In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone
- PMID: 1416868
- PMCID: PMC192050
- DOI: 10.1128/AAC.36.8.1788
In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone
Abstract
We determined the in vitro susceptibilities of eight Borrelia burgdorferi isolates to five oral cephalosporins. MICs for B. burgdorferi 297 were 23 micrograms/ml (cephalexin), 45 micrograms/ml (cefadroxil), 91 micrograms/ml (cefaclor), 0.13 microgram/ml (cefuroxime), 0.8 microgram/ml (cefixime), and 0.02 microgram/ml (ceftriaxone). When B. burgdorferi isolates were exposed to concentrations twice the MIC of cefuroxime, cefixime, or ceftriaxone, at least 72 h of incubation was required to kill 99% of the organisms.
Similar articles
-
In vitro activity of eight oral cephalosporins against Borrelia burgdorferi.Int J Antimicrob Agents. 2003 Apr;21(4):313-8. doi: 10.1016/s0924-8579(03)00005-0. Int J Antimicrob Agents. 2003. PMID: 12672576
-
Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.Antimicrob Agents Chemother. 1999 Dec;43(12):3030-2. doi: 10.1128/AAC.43.12.3030. Antimicrob Agents Chemother. 1999. PMID: 10582905 Free PMC article.
-
Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.Antimicrob Agents Chemother. 1990 Nov;34(11):2133-6. doi: 10.1128/AAC.34.11.2133. Antimicrob Agents Chemother. 1990. PMID: 2073103 Free PMC article.
-
Use of third-generation cephalosporins. Spirochetes.Hosp Pract (Off Ed). 1991;26 Suppl 4:34-9; discussion 53-4. doi: 10.1080/21548331.1991.11707733. Hosp Pract (Off Ed). 1991. PMID: 1918214 Review.
-
Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.Wien Klin Wochenschr. 2006 Nov;118(21-22):659-68. doi: 10.1007/s00508-006-0693-z. Wien Klin Wochenschr. 2006. PMID: 17160604 Review.
Cited by
-
Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.Antimicrob Agents Chemother. 1993 Jun;37(6):1329-33. doi: 10.1128/AAC.37.6.1329. Antimicrob Agents Chemother. 1993. PMID: 8328782 Free PMC article.
-
Current and emerging approaches for eliminating Borrelia burgdorferi and alleviating persistent Lyme disease symptoms.Front Microbiol. 2024 Sep 13;15:1459202. doi: 10.3389/fmicb.2024.1459202. eCollection 2024. Front Microbiol. 2024. PMID: 39345262 Free PMC article. Review.
-
In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.Antimicrob Agents Chemother. 1996 Nov;40(11):2632-6. doi: 10.1128/AAC.40.11.2632. Antimicrob Agents Chemother. 1996. PMID: 8913478 Free PMC article.
-
Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans.Antimicrob Agents Chemother. 1995 Mar;39(3):661-7. doi: 10.1128/AAC.39.3.661. Antimicrob Agents Chemother. 1995. PMID: 7793869 Free PMC article. Clinical Trial.
-
In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease.Drug Des Devel Ther. 2018 Sep 11;12:2915-2921. doi: 10.2147/DDDT.S164966. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30254421 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources